TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES AS LSD1 INHIBITORS
First Claim
Patent Images
30-1. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each Ra1 is independently selected from H, C1-6 alkyl, and Cy4;
- wherein said C1-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Cy4, halo, CN, ORa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, NRc3Rd3, NRc3C(O)Rb3, S(O)2Rb3, and S(O)2NRc3Rd3.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-a]pyrazine derivatives which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
41 Citations
45 Claims
-
30-1. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein each Ra1 is independently selected from H, C1-6 alkyl, and Cy4;
- wherein said C1-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from Cy4, halo, CN, ORa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, NRc3Rd3, NRc3C(O)Rb3, S(O)2Rb3, and S(O)2NRc3Rd3.
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeIncyte Corporation, Incyte Holdings Corporation (Incyte Corporation)
-
Original AssigneeIncyte Corporation
-
InventorsWang, Xiaozhao, Yao, Wenqing, Zhang, Colin, Wu, Liangxing
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current1/1
-
CPC Class CodesA61P 35/00 Antineoplastic agentsC07D 471/04 Ortho-condensed systemsC07D 487/04 Ortho-condensed systems
